Bandar Saeed Al-Ghamdi1,2, Dileep Kumar Rohra3, Gheid Ali Ibrahim Abuharb4, Hala Abdulrahman Alkofide4, Nadiah Salem AlRuwaili1, Mohamed M Shoukri5, Peter M B Cahusac3,6. 1. a Department of Cardiology, Heart Centre , King Faisal Specialist Hospital & Research Centre , Riyadh , Saudi Arabia. 2. b Department of Medicine , Alfaisal University , Riyadh , Saudi Arabia. 3. c Department of Pharmacology, College of Medicine , Alfaisal University , Riyadh , Saudi Arabia. 4. d Clinical Audiology, Department of Otolaryngology, Head & Neck Surgery and Communication Sciences , King Faisal Specialist Hospital & Research Centre , Riyadh , Saudi Arabia. 5. e Department of Cell Biology and the National Biotechnology Centre , King Faisal Specialist Hospital & Research Centre , Riyadh , Saudi Arabia , and. 6. f Department of Comparative Medicine , King Faisal Specialist Hospital & Research Center , Riyadh , Saudi Arabia.
Abstract
OBJECTIVE: This study was conducted to investigate the hypothesis that patients using β-blockers will develop hearing loss. DESIGN: A cross-sectional study. STUDY SAMPLE: A total of 125 patients completed the study. A total of 63 patients were on β-blockers and 62 were not on β-blockers. RESULTS: Carvedilol was significantly associated with hearing loss. Other beta-blockers including metoprolol and atenolol showed no association with hearing loss. Linear multiple regression analysis was run including variables of gender, age, ischaemic heart disease, cardiac failure/dilated cardiomyopathy, frusemide and carvedilol use as predictors for total hearing loss severity at all frequencies. Age and gender, as well as carvedilol, were found to be the only statistically significant predictors for hearing loss severity. CONCLUSION: Chronic use of carvedilol was associated with significant hearing loss. This may need to be taken into account when prescribing the drug. Further randomised controlled studies with baseline audiometric hearing tests before starting treatment, and periodic follow-up tests, would provide a better assessment of the effect of carvedilol on hearing.
OBJECTIVE: This study was conducted to investigate the hypothesis that patients using β-blockers will develop hearing loss. DESIGN: A cross-sectional study. STUDY SAMPLE: A total of 125 patients completed the study. A total of 63 patients were on β-blockers and 62 were not on β-blockers. RESULTS:Carvedilol was significantly associated with hearing loss. Other beta-blockers including metoprolol and atenolol showed no association with hearing loss. Linear multiple regression analysis was run including variables of gender, age, ischaemic heart disease, cardiac failure/dilated cardiomyopathy, frusemide and carvedilol use as predictors for total hearing loss severity at all frequencies. Age and gender, as well as carvedilol, were found to be the only statistically significant predictors for hearing loss severity. CONCLUSION: Chronic use of carvedilol was associated with significant hearing loss. This may need to be taken into account when prescribing the drug. Further randomised controlled studies with baseline audiometric hearing tests before starting treatment, and periodic follow-up tests, would provide a better assessment of the effect of carvedilol on hearing.
Entities:
Keywords:
Beta blockers; audiometry; beta adrenergic receptor; carvedilol; hearing loss
Authors: Maria Antonietta Barbieri; Giuseppe Cicala; Paola Maria Cutroneo; Eleonora Mocciaro; Laura Sottosanti; Francesco Freni; Francesco Galletti; Vincenzo Arcoraci; Edoardo Spina Journal: Front Pharmacol Date: 2019-10-08 Impact factor: 5.810
Authors: Shipra Gandhi; Manu R Pandey; Elizabeth A Repasky; Marc S Ernstoff; Kristopher Attwood; Wenyan Ji; Agnieszka K Witkiewicz; Erik S Knudsen; Cheryl Allen; Joseph D Tario; Paul K Wallace; Carlos D Cedeno; Maria Levis; Suzanne Stack; Pauline Funchain; Joseph J Drabick; Mark J Bucsek; Igor Puzanov; Hemn Mohammadpour Journal: Clin Cancer Res Date: 2020-10-30 Impact factor: 13.801